|
HY-W133891-100g
|
MedChemexpress LLC
|
Peptone from soya [CAS 91079-46-8]
|
|
|
|
|
HY-W133891-25g
|
MedChemexpress LLC
|
Peptone from soya [CAS 91079-46-8]
|
|
|
|
|
HY-139201-10mg
|
MedChemexpress LLC
|
Poly-D-lysine hydrobromide (MW 30000-70000) [CAS 27964-99-4]
|
|
Cancer-programmed cell death
|
|
|
HY-139201-5mg
|
MedChemexpress LLC
|
Poly-D-lysine hydrobromide (MW 30000-70000) [CAS 27964-99-4]
|
|
Cancer-programmed cell death
|
|
|
HY-139201A-10mg
|
MedChemexpress LLC
|
Poly-D-lysine hydrobromide (MW 70000-150000) [CAS 27964-99-4]
|
|
Cancer-programmed cell death
|
|
|
HY-139201A-25mg
|
MedChemexpress LLC
|
Poly-D-lysine hydrobromide (MW 70000-150000) [CAS 27964-99-4]
|
|
Cancer-programmed cell death
|
|
|
HY-139201A-5mg
|
MedChemexpress LLC
|
Poly-D-lysine hydrobromide (MW 70000-150000) [CAS 27964-99-4]
|
|
Cancer-programmed cell death
|
|
|
HY-126437D-10mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW ?300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437D-5mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW ?300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437C-10mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 150000-300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437C-25mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 150000-300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437C-5mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 150000-300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437C-50mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 150000-300000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437B-10mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 70000-150000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437B-5mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrobromide) (MW 70000-150000) [CAS 25988-63-0]
|
|
|
|
|
HY-126437A-10mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrochloride) [CAS 26124-78-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-126437A-5mg
|
MedChemexpress LLC
|
Poly-L-lysine (hydrochloride) [CAS 26124-78-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-131183-10mg
|
MedChemexpress LLC
|
PROTAC PD-1/PD-L1 degrader-1 [CAS 2447066-37-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-131183-100mg
|
MedChemexpress LLC
|
PROTAC PD-1/PD-L1 degrader-1 [CAS 2447066-37-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-131183-25mg
|
MedChemexpress LLC
|
PROTAC PD-1/PD-L1 degrader-1 [CAS 2447066-37-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-131183-5mg
|
MedChemexpress LLC
|
PROTAC PD-1/PD-L1 degrader-1 [CAS 2447066-37-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-131183-50mg
|
MedChemexpress LLC
|
PROTAC PD-1/PD-L1 degrader-1 [CAS 2447066-37-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-P3414A-1mg
|
MedChemexpress LLC
|
Proteasome-activating peptide 1 (TFA)
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P3414A-10mg
|
MedChemexpress LLC
|
Proteasome-activating peptide 1 (TFA)
|
|
Neuroscience-Neurodegeneration
|
|
|
HY-P3414A-5mg
|
MedChemexpress LLC
|
Proteasome-activating peptide 1 (TFA)
|
|
Neuroscience-Neurodegeneration
|
|
